Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

794
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
794
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

442
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
442

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pediatric Skin Disease Frequencies and Dermatology Use by Race and Ethnicity in US Children's Hospitals.

JAMA dermatology·2026
Same author

Generative Artificial Intelligence Tools: Evaluating Ways to Automate Your SALT (GATEWAYS) Scoring of Alopecia Areata.

Pediatric dermatology·2026
Same author

Leg Length Discrepancy in Patients With Lower Extremity Cutis Marmorata Telangiectatica Congenita: A Multicenter Retrospective Study.

Pediatric dermatology·2026
Same author

Reply to "Comment on 'Digitizing Diagnoses: Distinguishing Infantile Hemangiomas From Other Vascular Anomalies'".

Pediatric dermatology·2026
Same author

Cutaneous adverse events associated with mitogen activated protein kinase inhibitors for the treatment of vascular anomalies: A dual-center retrospective study.

Journal of the American Academy of Dermatology·2025
Same author

Expanding the phenotype of CARS1 variants to include congenital hyperinsulinism.

BMC medical genomics·2025
Same journal

Adverse Childhood Experiences and Pediatric Dermatology: Implications for Care, Equity, and Research.

Pediatric dermatology·2026
Same journal

State-of-the-Art Review: Vaccination in Pediatric Dermatology Patients Receiving Immunosuppressive or Immunomodulatory Therapy: A Review.

Pediatric dermatology·2026
Same journal

Multisystem Mucosal Morbidity in Recessive Dystrophic Epidermolysis Bullosa Inversa.

Pediatric dermatology·2026
Same journal

Infantile Transient Smooth Muscle Contraction of the Skin in Two Sisters.

Pediatric dermatology·2026
Same journal

Are 2021 CMS Changes Enough to Address the Pediatric Dermatology Crisis?

Pediatric dermatology·2026
Same journal

Annular Eruption in 12-Year-Old Boy.

Pediatric dermatology·2026
查看所有相关文章

相关实验视频

Updated: Jun 28, 2025

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

22.9K

加快的兰醇初始剂量 (RAPID) 的治疗方案

Charles Y Huang1, Marissa J Perman2,3, Albert C Yan2,3

  • 1Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Pediatric dermatology
|April 17, 2024
PubMed
概括
此摘要是机器生成的。

在婴儿血瘤中,以2mg/kg/天的剂量开始用普拉诺洛尔治疗,与以1mg/kg/天的剂量开始治疗一样安全. 在最近的一项研究中,这种用于婴儿血瘤治疗的加快剂量没有增加不良事件.

关键词:
婴儿血瘤 (英语:Infantile hemangioma) 是一种婴儿血瘤.这种药物是propranolol.

更多相关视频

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.5K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

相关实验视频

Last Updated: Jun 28, 2025

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

22.9K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.5K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

科学领域:

  • 儿科药理学 儿科药理学
  • 皮肤病学 皮肤病学
  • 血管异常 血管异常

背景情况:

  • 婴儿血管瘤是常见的儿科血管瘤.
  • 甲醇是一种有效的治疗方法,但会带来降血糖和心等风险.
  • 目前的指导方针建议以1毫克/公斤/天开始用普拉诺洛尔,并定位至2毫克/公斤/天.

研究的目的:

  • 为了比较婴儿和婴儿血瘤儿童的不良事件发生率.
  • 为了评估开始使用普拉诺洛尔2毫克/千克/天和1毫克/千克/天的安全性.

主要方法:

  • 对244名因婴儿血瘤而接受治疗的患者进行了回顾性队列研究.
  • 患者根据初始普拉拉诺洛尔剂量进行分类:1 mg/kg/天或2 mg/kg/天.
  • 主要结局包括家长报告的不良事件,低血压和心.

主要成果:

  • 在1毫克/公斤/天和2毫克/公斤/天开始组之间,不存在不良事件的显著差异 (p=0.057).
  • 婴儿开始服用2mg/kg/天的年龄或体重相关不良事件的发生率没有增加.
  • 该研究包括123名1毫克/公斤/天的患者和121名2毫克/公斤/天的患者.

结论:

  • 在婴儿血瘤治疗中,以每天2毫克/公斤的剂量开始使用普拉诺洛尔与不良事件的增加无关.
  • 这些发现支持加快普拉诺洛尔初始剂量的临床实践.
  • 这项研究提供了潜在更有效的治疗方法的证据.